[Stereotactic body radiotherapy. How to better protect normal tissues?]
Radiothérapie stéréotaxique extra crânienne. Comment mieux protéger les tissus sains ?
Dose Fractionation, Radiation
Humans
Magnetic Resonance Imaging, Interventional
/ methods
Medical Errors
/ prevention & control
Organs at Risk
/ radiation effects
Radiation Dose Hypofractionation
Radiation Injuries
/ prevention & control
Radiosurgery
/ education
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
/ standards
Radiotherapy, Image-Guided
/ methods
Normal tissues
Organes à risque
Organs at risk
Radiothérapie en conditions stéréotaxiques extra crânienne
Stereotactic body radiotherapy
Tissus sains
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
18
06
2019
revised:
10
07
2019
accepted:
11
07
2019
pubmed:
27
8
2019
medline:
8
10
2019
entrez:
27
8
2019
Statut:
ppublish
Résumé
The use of stereotactic body radiotherapy (SBRT) has increased rapidly over the past decade. Optimal preservation of normal tissues is a major issue because of their high sensitivity to high doses per session. Extreme hypofractionation can convert random errors into systematic errors. Optimal preservation of organs at risk requires first of all a rigorous implementation of this technique according to published guidelines. The robustness of the imaging modalities used for planning, and training medical and paramedical staff are an integral part of these guidelines too. The choice of SBRT indications, dose fractionation, dose heterogeneity, ballistics, are also means of optimizing the protection of normal tissues. Non-coplanarity and tracking of moving targets allow dosimetric improvement in some clinical settings. Automatic planning could also improve normal tissue protection. Adaptive SBRT, with new image guided radiotherapy modalities such as MRI, could further reduce the risk of toxicity.
Identifiants
pubmed: 31447339
pii: S1278-3218(19)30329-4
doi: 10.1016/j.canrad.2019.07.153
pii:
doi:
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
630-635Informations de copyright
Copyright © 2019 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.